Compare Alexandria Real Estate Equities Inc (ARE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Summit Therapeutics Inc — how do they compare? Alexandria Real Estate Equities Inc trades at $48.49 (market cap $8.34B), while Summit Therapeutics Inc trades at $15.29 (market cap $11.84B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Alexandria Real Estate Equities Inc pays a 6.02% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ARE | SMMT | |
|---|---|---|
Market Cap | $8.34B | $11.84B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $29.32 |
52-Week Low | $40.41 | $13.05 |
Enterprise Value | $20.80B | $11.26B |
Dividend Yield | 6.02% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
